| Authors: |
Locke FL; Moffitt Cancer Center, Tampa, Florida. Electronic address: Frederick.locke@moffitt.org., Nikiforow S; Dana-Farber Cancer Institute, Boston, Massachusetts., Frigault MJ; Massachusetts General Hospital, Boston, Massachusetts., Maloney DG; Fred Hutchinson Cancer Center, Seattle, Washington., Davila M; Roswell Park, Buffalo, New York., Miklos DB; Stanford University, Stanford, California., Lin Y; Mayo Clinic, Rochester, Minnesota., Vong J; A2 Biotherapeutics, Inc., Agoura Hills, California., Shah NN; Medical College of Wisconsin, Milwaukee, Wisconsin., Neelapu SS; The University of Texas MD Anderson Cancer Center, Houston, Texas., Welch J; A2 Biotherapeutics, Inc., Agoura Hills, California., Ng E; A2 Biotherapeutics, Inc., Agoura Hills, California., Jacobson C; Dana-Farber Cancer Institute, Boston, Massachusetts., Maus MV; Massachusetts General Hospital, Boston, Massachusetts. |
